Mineralys Therapeutics Inc. (MLYS) continues to advance its aldosterone synthase inhibitor program with pivotal trial recognition, strengthened financials, and upcoming data readouts that place the company on the radar for investors tracking developments in hypertension and cardiorenal therapies.
Company Overview
This Radnor, Pennsylvania-based clinical-stage biopharmaceutical company focuses on developing therapies for diseases driven by dysregulated aldosterone.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.